Purpose Of Review: In this article, we briefly summarise the current knowledge about human epidermal growth factor receptor 2 (HER2) alterations in colorectal cancer (CRC) and provide an overview of the latest published evidence especially regarding standardisation of detection methods/diagnostic criteria, prognostication, prediction and targeted treatments.
Recent Findings: Over the last 18 months, the results of many studies have been presented confirming the therapeutic potential of established anti-HER2 agents either as a monotherapy or in combination, as well as new anti-HER2 agents like antibody-drug-conjugates and tyrosine kinase inhibitors. Also, we have seen confirmation of the utility of liquid biopsy and ctDNA analyses as tool for HER2 detection and patient selection.
Summary: Despite concerning only 5% of metastatic CRC, HER2 represents a valuable target for emerging anti-HER2 therapies that might significantly improve the outcome of these patients. Standardising HER2 detection methods/diagnostic criteria, and producing high-quality, randomised evidence are the next challenges to meet the standards of regulatory authorities and ultimately have anti-HER2 agents available for use in routine practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CCO.0000000000000842 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing combination targeted immunotoxin therapy: Insights from HER2 and EpCAM expression profiles.
Biochem Biophys Res Commun
December 2024
Moscow Center for Advanced Studies, Kulakova Str. 20, 123592, Moscow, Russia; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10 Miklukho-Maklaya St., 117997, Moscow, Russia. Electronic address:
Molecular targeted cancer therapy is a rapidly developing field, driving progress toward greater treatment efficacy. However, targeted monotherapy often fails due to the development of multidrug resistance in tumors. The combination of multiple targeted agents emerges as a possible solution to enhance treatment outcomes by activating different signaling pathways.
View Article and Find Full Text PDFPrognostic value of HER2 2 + expression in patients with TNBC receiving adjuvant capecitabine.
Clin Transl Oncol
December 2024
Dr Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Health Sciences University, Ankara, Turkey.
Background: In triple-negative breast cancer (TNBC) patients receiving adjuvant capecitabine, the impact of HER2 expression on survival outcomes is unclear.
Methods: Between June 2017 and December 2023, 112 patients with TNBC who received adjuvant capecitabine due to residual masses after neoadjuvant chemotherapy (NACT) in three hospitals were identified. HER2 is analyzed through immunohistochemistry (IHC) and/or in situ hybridization in the core biopsy and/or post-surgical histopathologies.
Introduction: Bone-only metastasis (BOM) is a distinct clinical phenomenon in which cancer cells disseminate exclusively to the bone, without involvement of other distant organs. We investigated the factors associated with the BOM state vs. other states of metastasis in breast cancer patients with bone metastasis (BM) at their first relapse.
View Article and Find Full Text PDFA novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive heavily pretreated solid tumors: results from a phase Ia/Ib first-in-human, open-label, single center study.
Front Immunol
December 2024
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Background: IAH0968 is an afucosylated anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody which improved the activity of antibody-dependent cellular cytotoxicity (ADCC) and superior anti-tumor efficacy.
Methods: To determine the maximum tolerated dose (MTD) with dose-limiting toxicity (DLT), a single institution, phase Ia/Ib study was undertaken, using 3 + 3 design. The primary endpoints were safety, tolerability and preliminary clinical activity.
Combined systemic treatments in two patients with ductal salivary carcinoma.
Medicina (B Aires)
December 2024
Departamento de Clínica Oncológica, Instituto de Oncología Ángel H. Roffo, Buenos Aires, Argentina.
Ductal carcinomas, a variant of salivary gland cancer, are characterized by concurrent androgen receptor (AR) positivity and overexpression of HER2, making them potential targets for tailored therapies extensively explored in literature. We present two consecutive cases of patients diagnosed with inoperable metastatic ductal carcinoma, both displaying HER2 overexpression and AR positivity, who underwent combination therapy involving chemotherapy and dual targeted agents. Both patients diagnosed with centralized inoperable ductal carcinoma were retrospectively analyzed and received trastuzumab, docetaxel, leuprolide and bicalutamida as first-line therapy until progression, defined by RECIST criteria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!